Online citations, reference lists, and bibliographies.
← Back to Search

Determinants Of Malignant Pleural Mesothelioma Survival And Burden Of Disease In France: A National Cohort Analysis

C. Chouaid, J. B. Assié, P. Andujar, C. Blein, C. Tournier, A. Vainchtock, A. Scherpereel, I. Monnet, J. Pairon
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This study was undertaken to determine the healthcare burden of malignant pleural mesothelioma (MPM) in France and to analyze its associations with socioeconomic deprivation, population density, and management outcomes. A national hospital database was used to extract incident MPM patients in years 2011 and 2012. Cox models were used to analyze 1‐ and 2‐year survival according to sex, age, co‐morbidities, management, population‐density index, and social deprivation index. The analysis included 1,890 patients (76% men; age: 73.6 ± 10.0 years; 84% with significant co‐morbidities; 57% living in urban zones; 53% in highly underprivileged areas). Only 1% underwent curative surgical procedure; 65% received at least one chemotherapy cycle, 72% of them with at least one pemetrexed and/or bevacizumab administration. One‐ and 2‐year survival rates were 64% and 48%, respectively. Median survival was 14.9 (95% CI: 13.7–15.7) months. The mean cost per patient was 27,624 ± 17,263 euros (31% representing pemetrexed and bevacizumab costs). Multivariate analyses retained men, age >70 years, chronic renal failure, chronic respiratory failure, and never receiving pemetrexed as factors of poor prognosis. After adjusting the analysis to age, sex, and co‐morbidities, living in rural/semi‐rural area was associated with better 2‐year survival (HR: 0.83 [95% CI: 0.73–0.94]; P < 0.01); social deprivation index was not significantly associated with survival. With approximately 1,000 new cases per year in France, MPMs represents a significant national health care burden. Co‐morbidities, sex, age, and living place appear to be significant factors of prognosis.
This paper references
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1111/j.1445-5994.2012.02925.x
Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia
S. C.-H. Kao (2013)
10.1186/1471-2458-9-33
Ecological association between a deprivation index and mortality in France over the period 1997 – 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death
G. Rey (2009)
10.1038/bjc.2012.245
Prognosis and prognostic factors of patients with mesothelioma: a population-based study
S. van der Bij (2012)
10.1371/journal.pone.0145039
Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients
E. Taioli (2015)
Audit in England and Wales
M. Soeberg (2014)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1097/JTO.0b013e318275b346
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population-Based Study of 1686 Cases
Å. Helland (2012)
10.4135/9781483392271.n276
International Classification of Diseases--9th revision.
P. Loy (1978)
10.1136/thoraxjnl-2013-203744
Occupational and non-occupational attributable risk of asbestos exposure for malignant pleural mesothelioma
A. Lacourt (2014)
10.1016/j.lungcan.2009.08.019
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
S. Boeluekbas (2011)
10.1111/j.1524-4733.2007.00209.x
Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice.
A. Cordony (2008)
The French mesothelioma network
F. Galateau-Salle (2014)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
The French mesothelioma network from
F Galateau-Salle (1998)
Malignant pleural mesotheliomaand the Society of Thoracic Surgeons Database: an analysis ofsurgical morbidity and mortality
B. M. Burt (2014)
10.1002/ajim.22206
Potential years of life lost (PYLL) caused by asbestos-related diseases in the world.
Rachmania Diandini (2013)
Malignant pleural mesothelioma incidence and survival in the Republic of Ireland
C J Jennings (1994)
10.1097/JTO.0000000000000064
Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients
P. Bovolato (2014)
10.1093/JNCI/DJM257
In Australia, patients and government at odds over mesothelioma treatment costs.
Vicki Burkitt (2007)
10.1200/JCO.2017.73.8401
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
D. Nelson (2017)
10.1038/bjc.2014.478
Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales
A. Linton (2014)
Factors associated with survival inlarge series of patients with malignant pleural mesothelioma in New South Wales
A. Linton (2014)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomized, controlled, open-label
G Zalcman (2016)
10.3978/j.issn.2225-319X.2012.11.04
Malignant pleural mesothelioma: an epidemiological perspective.
Benjamin M. Robinson (2012)
10.1016/j.jtcvs.2012.09.023
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
M. Baud (2013)
Estimation des parts attribuables de cancers aux expositions professionnelles à l’amiante en France: utilisation des matrices développées dans le cadre du programme Matgéné
A. Gilg Soit Ilg (2015)
10.1016/j.lungcan.2015.03.005
Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.
P. Beckett (2015)
10.1186/s12885-015-1881-x
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
C. Raynaud (2015)
10.1196/annals.1371.042
The Economic Costs of Health Service Treatments for Asbestos‐Related Mesothelioma Deaths
A. Watterson (2006)
10.1016/j.jtcvs.2014.03.011
Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality.
B. Burt (2014)
10.1097/JTO.0b013e3181f1903e
Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology, and End Results [SEER]) Population
R. Flores (2010)
10.1016/j.canep.2013.12.002
Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
C. J. Jennings (2014)
Determinants of survival in malignant pleural mesothelioma: a Mesothelioma Management and Healthcare Burden C
E Taioli (2015)
10.1007/s10198-013-0528-6
Estimating the social cost of respiratory cancer cases attributable to occupational exposures in France
H. Serrier (2013)
Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
C. Blomberg (2015)
10.1038/bjc.2014.312
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
G. Ceresoli (2014)
10.1371/journal.pone.0182798
Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study)
C. Chouaïd (2017)
10.1007/s00520-013-1753-3
Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma
S. Kao (2013)
10.1183/09031936.00153611
Population-based survival for malignant mesothelioma after introduction of novel chemotherapy
R. Damhuis (2011)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar